DuPont Animal Nutrition, a DuPont Nutrition & Biosciences (DuPont) business unit, has announced a partnership with Proteon Pharmaceutics
The partnership will bring the emerging bacteriophage technology to poultry producers, helping to mitigate antimicrobial resistance (AMR).
The antimicrobial resistance threat has spurred recent investments in bacteriophageal technologies. Modern analytics and omics technologies have enabled the bacteriophage candidates to be screened and identified for a specific bacterial challenge, with significant implications for feed and food safety. This new technology is already being used in the animal feed industry.
DuPont invited Proteon Pharmaceuticals to partner with them for their compatible work culture, solid scientific approach and leading position in the field of phage technology
Poultry farmers in selected markets already benefit from using Proteon’s technology to ensure biosecurity through the waterline and to improve the efficiency of the production.
Aart Mateboer, business leader, DuPont Animal Nutrition, said, “Proteon Pharmaceuticals is a pioneer in bacteriophage technology used in animal farming. They have been developing this technology for more than 10 years. It has been tested in Europe and Asia and proven in terms of efficacy and stability.
“This technology fits with our nutribiotic approach. We are pleased to add it to our range of solutions for poultry producers.”
Jarosław Dastych, CEO, Proteon Pharmaceuticals, commented, “We strongly believe that our technology might be considered as the future of animal health and nutrition and will help to reduce antibiotic use and antimicrobial resistance.
“We are excited to take this next step with DuPont to bring the benefits of bacteriophage technology as a feed additive to poultry producers globally.”
